Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
NCT ID: NCT01584843
Last Updated: 2015-07-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
41 participants
INTERVENTIONAL
2012-05-31
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Botox Instead of Strabismus Surgery (BISS)
NCT03459092
Botulinum Toxin Injection Versus Prism Treatment in Small-angle Acute Acquired Concomitant Esotropia
NCT06714877
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
NCT01896895
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity
NCT01153815
Comparison of Two Treatments for Strabismus Correction: Botulinum Toxin A Associated to Surgery and Surgery Alone
NCT01460355
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-treatment (10-20 PD)
Receive no treatment on Week 0
No interventions assigned to this group
GSK1358820 1.25 U (10-20 PD)
Receive 1.25 U of GSK1358820 on Week 0
GSK1358820
IM injection of Botulinum Toxin Type A
GSK1358820 2.5 U (10-20 PD)
Receive 2.5 U of GSK1358820 on Week 0
GSK1358820
IM injection of Botulinum Toxin Type A
Non-treatment (20-50 PD)
Receive no treatment on Week 0
No interventions assigned to this group
GSK1358820 2.5 U (20-50 PD)
Receive 2.5 U of GSK1358820 on Week 0
GSK1358820
IM injection of Botulinum Toxin Type A
GSK1358820 5.0 U (20-50 PD)
Receive 5.0 U of GSK1358820 on Week 0
GSK1358820
IM injection of Botulinum Toxin Type A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK1358820
IM injection of Botulinum Toxin Type A
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Paralytic or concomitant strabismus. Subjects with paralytic strabismus will be eligible for inclusion only if paralysis has persisted for at least 3 months and strabismus has been developed at one eye
* Horizontal deviations (esotropia or exotropia)
* Strabismus with the (absolute) strabismus angles at both distance and near of primary position \>-10 PD and \<50 PD
* Age\>-12 years at the time of giving informed consent
* The subject has to be capable of giving written informed consent of their own will. For subjects aged less than 20 years, the subject and his/her legally acceptable representative (person in parental authority or guardian) have to give written informed consent
* Either sex. Males have to agree to practice contraception during the study period. Females of child-bearing potential will be eligible for inclusion in this study. However, they have to have negative pregnancy test both at the screening visit and just before initial injection and agree to practice reliable methods of contraception
* QTc \<450 msec; for patients with Bundle Branch Block, QTc \<480 msec based on average QTc value of triplicate ECGs \<At the start of treatment period \>
* Strabismus with the (absolute) strabismus angles at both distance and near of primary position \>-10 PD and \<50 PD
* ALT at the screening visit \<2 x ULN and alkaline phosphatase and bilirubin \<-1.5 x ULN
Exclusion Criteria
* Secondary strabismus caused by prior surgical recession of the antagonist in past surgical treatment of strabismus
* Strabismus due to abnormal innervations
* Strabismus with thyroid-associated ophthalmopathy
* Strabismus with strong motor limitation of extraocular muscles
* Mechanical limitations of ocular movement due to periorbital disease or due to past surgical treatment other than strabismus
* Blepharoptosis
* Conjunctival pathology
* Systemic neuromuscular junction dysfunction
* Systemic neuromuscular disease
* Past treatment with botulinum toxin
* Planned injections of botulinum toxin for other indication(s) or for cosmetic purpose during the study period
* Known hypersensitivity to any of the drugs to be used in the study or history of allergy
* Treatment with antibiotics with neuromuscular junction inhibitory action such as aminoglycosides, polypeptides, tetracyclines and lincomycins, except those contained in topical antibacterial formulations
* Treatment with muscle relaxants or drugs with muscle relaxant action
* Chronic respiratory disorder
* Severe muscle weakness or atrophy
* Angle-closure glaucoma or its predisposing factors
* Severe cardiac, hepatic or renal impairment. The severity refers to Grade 3 according to "the Classification of the Severity of Adverse Experiences" (MHLW PAB/SD Notification No. 80, dated 29 June 1992).
* Surgical operation or hospitalization to be needed during the study period
* Female subjects who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study period
* Participation in another clinical study within 6 months prior to enrollment in this study or planned participation in another clinical study after enrollment in this study
* Psychiatric disorder or impairment of intellectual function that may affect the subject's ability to give informed consent or to comply with the trial procedures
* History of alcohol dependence or drug abuse
* Subjects whom the investigator (or sub-investigator) considers ineligible for the study
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Aichi, , Japan
GSK Investigational Site
Fukuoka, , Japan
GSK Investigational Site
Hyōgo, , Japan
GSK Investigational Site
Kagoshima, , Japan
GSK Investigational Site
Kanagawa, , Japan
GSK Investigational Site
Miyazaki, , Japan
GSK Investigational Site
Miyazaki, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Osaka, , Japan
GSK Investigational Site
Shizuoka, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Tokyo, , Japan
GSK Investigational Site
Yamaguchi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
116246
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.